Cosmos Health Inc. (COSM)
USD 0.33
(-3.77%)
USD 0.33
(-3.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 66.29 Million USD | -2.56% |
| 2022 | 68.03 Million USD | 37.65% |
| 2021 | 49.42 Million USD | 12.74% |
| 2020 | 43.84 Million USD | 83.61% |
| 2019 | 23.87 Million USD | 15.39% |
| 2018 | 20.69 Million USD | 93.85% |
| 2017 | 10.67 Million USD | 242.33% |
| 2016 | 3.11 Million USD | 374.21% |
| 2015 | 657.62 Thousand USD | -90.91% |
| 2014 | 7.23 Million USD | 734.39% |
| 2013 | 867.05 Thousand USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 15.23 Thousand USD | 3142.13% |
| 2010 | 470.00 USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 62.34 Million USD | -5.96% |
| 2024 Q2 | 60.82 Million USD | -2.43% |
| 2023 FY | 66.29 Million USD | -2.56% |
| 2023 Q1 | 68.01 Million USD | -0.03% |
| 2023 Q4 | 66.29 Million USD | -7.31% |
| 2023 Q2 | 68.59 Million USD | 0.85% |
| 2023 Q3 | 71.52 Million USD | 4.28% |
| 2022 Q3 | 45.62 Million USD | -4.64% |
| 2022 FY | 68.03 Million USD | 37.65% |
| 2022 Q1 | 49.77 Million USD | 0.7% |
| 2022 Q2 | 47.84 Million USD | -3.88% |
| 2022 Q4 | 68.03 Million USD | 49.14% |
| 2021 Q1 | 41.69 Million USD | -4.9% |
| 2021 FY | 49.42 Million USD | 12.74% |
| 2021 Q2 | 45.15 Million USD | 8.3% |
| 2021 Q3 | 47.67 Million USD | 5.58% |
| 2021 Q4 | 49.42 Million USD | 3.67% |
| 2020 Q1 | 23.47 Million USD | -1.71% |
| 2020 FY | 43.84 Million USD | 83.61% |
| 2020 Q2 | 33.85 Million USD | 44.23% |
| 2020 Q3 | 38.56 Million USD | 13.93% |
| 2020 Q4 | 43.84 Million USD | 13.68% |
| 2019 Q4 | 23.87 Million USD | 12.22% |
| 2019 FY | 23.87 Million USD | 15.39% |
| 2019 Q1 | 21.7 Million USD | 4.88% |
| 2019 Q2 | 21.83 Million USD | 0.57% |
| 2019 Q3 | 21.28 Million USD | -2.52% |
| 2018 Q1 | 13.4 Million USD | 25.57% |
| 2018 Q4 | 20.69 Million USD | 6.09% |
| 2018 Q3 | 19.5 Million USD | 43.61% |
| 2018 Q2 | 13.58 Million USD | 1.32% |
| 2018 FY | 20.69 Million USD | 93.85% |
| 2017 FY | 10.67 Million USD | 242.33% |
| 2017 Q4 | 10.67 Million USD | -1.47% |
| 2017 Q3 | 10.83 Million USD | 49.48% |
| 2017 Q2 | 7.24 Million USD | 65.09% |
| 2017 Q1 | 4.39 Million USD | 40.8% |
| 2016 Q4 | 3.11 Million USD | 48.08% |
| 2016 FY | 3.11 Million USD | 374.21% |
| 2016 Q3 | 2.1 Million USD | 136.6% |
| 2016 Q2 | 890.09 Thousand USD | 0.35% |
| 2016 Q1 | 887.02 Thousand USD | 34.88% |
| 2015 Q1 | 6.36 Million USD | -12.04% |
| 2015 FY | 657.62 Thousand USD | -90.91% |
| 2015 Q4 | 657.62 Thousand USD | -89.85% |
| 2015 Q3 | 6.47 Million USD | 0.88% |
| 2015 Q2 | 6.42 Million USD | 0.94% |
| 2014 FY | 7.23 Million USD | 734.39% |
| 2014 Q4 | 7.23 Million USD | 0.2% |
| 2014 Q3 | 7.22 Million USD | 243.19% |
| 2014 Q2 | 2.1 Million USD | 113.11% |
| 2014 Q1 | 987.23 Thousand USD | 13.86% |
| 2013 Q3 | 501.21 Thousand USD | 2560.95% |
| 2013 FY | 867.05 Thousand USD | 0.0% |
| 2013 Q4 | 867.05 Thousand USD | 72.99% |
| 2013 Q1 | 6143.00 USD | 1256.07% |
| 2013 Q2 | 18.83 Thousand USD | 206.63% |
| 2012 Q3 | 981.00 USD | 2352.5% |
| 2012 Q4 | 453.00 USD | -53.82% |
| 2012 FY | - USD | -100.0% |
| 2012 Q1 | 1506.00 USD | 3402.33% |
| 2012 Q2 | 40.00 USD | -97.34% |
| 2011 Q4 | 43.00 USD | -98.79% |
| 2011 Q1 | 61.44 Thousand USD | 6069.58% |
| 2011 Q2 | 15.23 Thousand USD | -75.2% |
| 2011 Q3 | 3558.00 USD | -76.65% |
| 2011 FY | 15.23 Thousand USD | 3142.13% |
| 2010 Q3 | 52.00 USD | -88.94% |
| 2010 Q2 | 470.00 USD | -95.38% |
| 2010 Q1 | 10.16 Thousand USD | -31.09% |
| 2010 Q4 | 996.00 USD | 1815.38% |
| 2010 FY | 470.00 USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | 14.75 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | 13.733% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 92.67% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -15.461% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 95.789% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -142.424% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -142.424% |
| SCYNEXIS, Inc. | 128.41 Million USD | 48.373% |
| Safety Shot Inc | 12.7 Million USD | -421.635% |
| Alpha Teknova, Inc. | 128.58 Million USD | 48.443% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 94.201% |
| Bright Green Corporation | 17.4 Million USD | -280.942% |
| Dynavax Technologies Corporation | 997.09 Million USD | 93.351% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 67.786% |
| PainReform Ltd. | 9.93 Million USD | -567.629% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -186.658% |
| Embecta Corp. | 1.21 Billion USD | 94.541% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 90.897% |
| Procaps Group, S.A. | 460.18 Million USD | 85.594% |
| Theratechnologies Inc. | 77.76 Million USD | 14.753% |
| Harrow Health, Inc. | 311.75 Million USD | 78.735% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -345.146% |
| Biofrontera Inc. | 27.93 Million USD | -137.346% |
| DURECT Corporation | 45.18 Million USD | -46.707% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 95.295% |
| Cronos Group Inc. | 1.13 Billion USD | 94.155% |
| OptiNose, Inc. | 107.72 Million USD | 38.461% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 85.927% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -18.493% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -187.652% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 85.589% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -456.256% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 18.93% |
| Radius Health, Inc. | 1.71 Billion USD | 96.137% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -24.412% |
| ProPhase Labs, Inc. | 91.92 Million USD | 27.882% |
| Phibro Animal Health Corporation | 982.18 Million USD | 93.25% |
| Procaps Group S.A. | 460.18 Million USD | 85.594% |
| Alvotech | 950.09 Million USD | 93.022% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -53.076% |
| Viatris Inc. | 47.68 Billion USD | 99.861% |
| Rockwell Medical, Inc. | 52.17 Million USD | -27.069% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 43.863% |
| SIGA Technologies, Inc. | 254.83 Million USD | 73.985% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.471% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 75.778% |
| Shineco, Inc. | 84.17 Million USD | 21.245% |
| PetIQ, Inc. | 868.22 Million USD | 92.364% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -685.659% |
| Incannex Healthcare Limited | 17.04 Million USD | -288.899% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.961% |
| Alimera Sciences, Inc. | 153.52 Million USD | 56.817% |
| Silver Spike Investment Corp. | 88.57 Million USD | 25.154% |
| Assertio Holdings, Inc. | 286.41 Million USD | 76.854% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1013.886% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -96.165% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -112.193% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -400.437% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 74.612% |
| Hempacco Co., Inc. | 18.04 Million USD | -267.429% |
| Talphera, Inc. | 20.39 Million USD | -225.058% |
| Alvotech | 950.09 Million USD | 93.022% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 83.677% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 95.985% |
| Currenc Group, Inc. | 141.49 Million USD | 53.145% |
| Kamada Ltd. | 351.96 Million USD | 81.164% |
| Indivior PLC | 1.95 Billion USD | 96.602% |
| Evoke Pharma, Inc. | 7.06 Million USD | -837.895% |
| Flora Growth Corp. | 23.62 Million USD | -180.604% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -400.437% |
| Evolus, Inc. | 188.99 Million USD | 64.923% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 94.82% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 95.618% |
| Akanda Corp. | 8.83 Million USD | -649.951% |